Cutler Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Cutler Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-9,900	Closed	-$4K	–	7318
2017 Q1	$4K	Buy	+9,900	New	+$119K	﹤0.01%	4988
2016 Q2	–	Sell	-900	Closed	-$5K	–	7491
2016 Q1	$5K	Sell	900 -1,800	-67%	-$25.9K	﹤0.01%	4919
2015 Q4	$3K	Buy	+2,700	New	+$58.7K	﹤0.01%	5426

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cutler Group's CNCE Position: Q2 2019 in Review

Cutler Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 200 shares — an estimated $2K sold.

Cutler Group first reported a position in CNCE in Q4 2015 and held it in 8 quarters. The position peaked at $45K in Q1 2017. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

Cutler Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Cutler Group sold 200 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
Cutler Group first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 8 quarters.
Cutler Group's Concert Pharmaceuticals, Inc. position peaked at $45K in Q1 2017.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Cutler Group's 13F filing for Q2 2019, filed 9 Aug 2019.